Thalomid

Thalomid

  • August 2018 •
  • 20 pages •
  • Report ID: 5779928 •
  • Format: PDF
Drug Overview
Thalomid (Celgene) contains thalidomide, a glutamic acid derivative that possesses immunomodulatory, anti-inflammatory, and anti-angiogenic properties. The drug’s mechanism of action is not fully understood, but it is presumed to inhibit both the production of tumor necrosis factor-alpha in stimulated peripheral monocytes, and the activities of interleukins and interferons. It also exhibits pro-angiogenic effects and is found to inhibit both the vascular endothelial growth factor and basic fibroblast growth factor.